Specialty Drug Trends in Workers’ Compensation
Alan Rook
Senior Clinical Account Executive, myMatrixx
In this episode, we discuss specialty drug trends and their impact on workers' compensation with Alan Rook. Topics include the legalization of cannabis and its implications, fentanyl exposure risks for first responders, trends in opioid use, the role of specialty drugs in treating chronic conditions and the evolving landscape of workers' compensation claims related to cancer presumption and PTSD. Alan also highlights ongoing changes in legislation, employer policies and medical practices.
*The views and opinions expressed in the Public Risk Management Association (PRIMA) blogs/podcasts are those of each respective author/speaker. The views and opinions do not necessarily reflect the official policy or position of PRIMA.*
Alan Rook
Senior Clinical Account Executive, myMatrixx
Summary of Qualifications
Alan has over 20 years of experience in the insurance industry and graduated from the University of South Florida with a business degree. He began his career working for Acordia, Inc. (now Wells Fargo Insurance Services) as an insurance broker providing insurance and risk management services, specializing in workers' compensation.
Responsibilities
As a Senior Clinical Account Executive, he serves as a liaison between myMatrixx and clients. He is responsible for providing support for new customer implementations, clinical program development, and client service support, which includes data analytics, formulary management, and clinical evaluation.
Additional responsibilities include providing onsite clinical services that promote safe and effective drug therapy while controlling drug costs and communicating and collaborating with various internal departments regarding clients' clinical initiatives.
Professional Affiliations
Professional designations included Associate in Risk Management (ARM), Certified Insurance Counselor (CIC), and Accredited Advisor in Insurance (AAI).
Education
University of South Florida College of Business BS degree
University of Florida College of Pharmacy; Doctor of Pharmacy degree (PharmD), 2013
